VBCR - February 2015, Volume 4, No 1 - In the Literature

Despite being the most common over-the-counter treatment for pain related to knee osteoarthritis (OA), acetaminophen was found inferior to other commonly used pain medications in a large network meta-analysis. Intra-articular (IA) treatments were superior to oral nonsteroidal anti-inflammatory drugs (NSAIDs) for pain relief in this study.

Lead author Raveendhara R. Bannuru, MD, and colleagues at Tufts Medical Center in Boston, Massachusetts, wrote that the superiority of IA treatments is possibly due to a placebo effect. “The information from this study, along with the safety profiles and relative costs of included treatments, should be helpful to clinicians when making care decisions tailored to individual patient needs,” they wrote.

In the absence of definitive head-to-head trials of medications used to treat knee OA, the authors conducted a large meta-analysis to get a handle on the comparative effectiveness of commonly used drugs in this setting. They reviewed a total of 33,243 participants in 137 randomized controlled trials published between 1980 and 2014; each trial compared 2 or more treatments for knee OA and reported at least 1 measure of pain, function, or stiffness. Studies were drawn from searches of MEDLINE, EMASE, Web of Science, Google, Scholar, and Cochrane Central Register of Controlled Trials, as well as unpublished data. Treatments studied included acetaminophen, diclofenac, ibuprofen, naproxen, celecoxib, IA corticosteroids, IA hyaluronic acid, oral placebo, and IA placebo. An absolute change of 20 points on a scale from 0 to 100 on the OA Research Society International-Outcome Measures in Rheumatology responder criteria was deemed clinically significant.

Reported outcomes differed in these trials; 129 trials with 32,129 participants contributed to the analyses of pain-related outcomes, 76 trials (24,059 participants) contributed to the analyses of physical function outcomes, and 55 trials (18,267 participants) contributed to the analyses of stiffness outcomes. Age of participants ranged from 45 to 76 years, and the proportion of women ranged from 3% to 100%.
All interventions were statistically superior to placebo for pain-related outcomes. The most efficacious pain relief occurred with IA hyaluronic acid and the least efficacious was acetaminophen; effect sizes (standard mean differences) were 0.63 and 0.18, respectively. All treatments except acetaminophen met the prespecified criteria for clinically significant improvement. All active treatments except celecoxib were statistically superior to acetaminophen; IA treatments were more effective than oral treatments.

All interventions were significantly superior to oral placebo for function, except IA corticosteroids. Naproxen, ibuprofen, diclofenac, and celecoxib were statistically significantly better than acetaminophen for functional outcomes. IA hyaluronic acid was significantly better than IA placebo and IA corticosteroids.
All oral treatments were significantly superior to acetaminophen for stiffness. IA hyaluronic acid was significantly better than IA placebo for stiffness.

Traditional nonselective NSAIDs were associated with more gastrointestinal (GI) adverse events and withdrawals compared with oral placebo and acetaminophen; GI adverse events were similar between acetaminophen and celecoxib. The short exposure time of 2 to 3 months probably affected reporting on adverse cardiovascular events, the authors wrote. Transient local reactions were the most commonly reported adverse events related to IA treatments, and the frequency was similar among IA therapies.

The network meta-analysis did not investigate combination therapies, even though these are commonly used to treat knee OA. “The large number of possible therapy combinations and scarcity of trials comparing these treatments prompted us to restrict our analysis to monotherapies,” the authors wrote.

Bannuru RR, et al. Ann Intern Med. 2015;162(1):46-54.

Related Items
In the Literature - December 2017
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in In the Literature
In the Literature - June 2017
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in In the Literature
Response to NSAID Treatment Similar Among Patients with AS and Nonradiographic Axial SpA
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in In the Literature
In the Literature - December 2016
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in In the Literature
In the Literature - November 2016
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in In the Literature
In the Literature - October 2016
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in In the Literature
In the Literature - August 2016
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in In the Literature
In the Literature - July 2016
VBCN - July 2016 Volume 3, No 2 published on July 25, 2016 in In the Literature
In the Literature - June 2016
VBCC - June 2016, Vol 7, No 5 published on June 17, 2016 in In the Literature
In the Literature - May 2016
VBCC - May 2016, Vol 7, No 4 published on June 3, 2016 in In the Literature
Last modified: May 21, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology